Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02040116 · ClinicalTrials.gov registry record · Phase 4
Study Evaluating Rapid Infusion Rituximab in Patients With Autoimmune Diseases
A Phase 4 study, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- Phase 4
- Development phase
- 19
- Enrollment target
NCT02040116: Completed Phase 4 study, sponsored by Wake Forest University Health Sciences.
NCT02040116 is a Phase 4 study that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 19 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02040116, a Phase 4 study, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 19 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the impact of rapid infusion rituximab on the incidence of infusion-related reactions in patients with Autoimmune Diseases.
Primary Outcome
Patients are given therapy on day 1 and if infusion is tolerated with \< grade 2 reaction based on the CTCAE v4 then then will proceed to rapid infusion on day 14 which is given over 90 minutes. The number of infusion reaction is measured for all patients and in all infusions given.
Interventions
- DRUG Rituximab Infusion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2013-02 |
| Est. Completion | 2014-08 |
| Phase | Phase 4 |
What the finished NCT02040116 record still lists
NCT02040116 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 19 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 1 intervention - of which Rituximab Infusion is the first listed.
NCT02040116 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02040116 about?
NCT02040116 is a clinical study titled "Study Evaluating Rapid Infusion Rituximab in Patients With Autoimmune Diseases". The purpose of this study is to evaluate the impact of rapid infusion rituximab on the incidence of infusion-related reactions in patients with Autoimmune Diseases.
What is the current status of trial NCT02040116?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 19 participants. The study started on 2013-02. Estimated completion is 2014-08.
What interventions are being tested in trial NCT02040116?
The interventions under investigation include: Rituximab Infusion (DRUG).
Who is sponsoring clinical trial NCT02040116?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02040116's enrollment target sits among peer trials
19 1834th of 2000 higher than 159 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03207464 · 19 participants · Phase 1
Molecular Imaging of NET Using [C-11]MRB-PET in MS
- NCT04318717 · 19 participants · Phase 2
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
- NCT05103904 · 19 participants · Phase 2
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
- NCT05607407 · 19 participants · Phase 2
Methimazole in Patients With Progressive Glioblastoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia